• V2ACT Therapeutics Announces IND for V2ACT Study for Pancreatic Cancer americanpharmaceuticalreview
    January 05, 2021
    V2ACT Therapeutics™ has obtained permission from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application and may proceed with the clinical investigation of V2ACT in a Phase 1/2a trial for the treatment of newly ...
PharmaSources Customer Service